Home › Soft Tissue Sarcoma › Arizona › Scottsdale
Soft Tissue Sarcoma clinical trials in Scottsdale, AZ
3 studies for Soft Tissue Sarcoma are looking for participants at sites in and around Scottsdale (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- HonorHealth Research Institute, Scottsdale
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
Recruiting
- Mayo Clinic in Arizona, Scottsdale
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingPhase 1/2
- Mayo Clinic in Arizona, Scottsdale
About Soft Tissue Sarcoma
Soft tissue sarcoma refers to cancer that begins in the muscle, fat, vessels or tendons. It can cause a lump or swelling. See which treatments are available
More about Soft Tissue Sarcoma on MedlinePlus
Soft Tissue Sarcoma trials in other cities
- Houston, TX32 studies
- New York City, NY19 studies
- Boston, MA18 studies
- St. Louis, MO14 studies
- Columbus, OH13 studies
- Los Angeles, CA13 studies
- Washington, DC12 studies
- Memphis, TN11 studies
- Philadelphia, PA10 studies
- Rochester, MN9 studies
- Nashville, TN9 studies
- Aurora, CO9 studies
Other studies in Scottsdale
- Cancer (all types)18 studies
- Breast Cancer18 studies
- Metastatic Cancer17 studies
- Prostate Cancer17 studies
- Non-Small Cell Lung Cancer15 studies
- Colorectal Cancer15 studies
- Pancreatic Cancer13 studies
- Melanoma10 studies
- Ulcerative Colitis8 studies
- Lung Cancer8 studies
- Alzheimer's Disease7 studies
- Liver Cancer (Hepatocellular Carcinoma)7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.